Concomitant boost radiotherapy schedules in the treatment of carcinoma of the oropharynx and nasopharynx.

Concomitant boost schedules are characterized by delivering the boost (10-12 fractions) as second daily treatments during rather than following the basic wide field irradiations. This results in shortening the overall time to administer 69-72 Gy from 7 1/2-8 weeks to 6 weeks, which we hoped would improve the tumor control rate by reducing the opportunity for tumor clonogens to regenerate during treatment. From August 1985 to August 1988, 79 patients with T2-4 carcinomas of the oropharynx (72 patients) or nasopharynx (7 patients) were treated according to 1 of the 3 variants of the concomitant boost technique. The median age of patients was 60 years (range: 19-84 years) and the male-to-female ratio was 2.6. The overall 2-year actuarial primary and nodal control rates by radiotherapy alone were 74% and 76%, respectively. The ultimate 2-year control rates after surgical salvage were 82% and 84%, respectively. If the boost given during the last 2-2 1/2 weeks of basic treatment, a slightly better primary control rate (p = 0.11) resulted than if the boost was delivered during the first 2-2 1/2 weeks or twice a week throughout the basic treatment. The 2-year actuarial primary control rate of the 13 patients receiving induction chemotherapy prior to radiotherapy was significantly lower than that of patients treated with radiation only (81% vs 34%, p = 0.01), but this could be partly attributed to a more advanced stage in the chemotherapy group. The acute mucosal reactions were, as expected, more severe than those observed with conventional fractionation. Fifty patients developed confluent mucositis covering more than half of the boost area. Such reactions lasted for more than 6 weeks in seven patients. Late complications, however, so far observed, have been few. Three patients experienced chronic mucosal tenderness, 1 chronic mucosal ulceration, 2 transient bone exposure, and 1 carotid rupture following salvage surgery. The results so far appear to be better than the outcome of conventional radiotherapy. Its real value will be determined in a prospective randomized study.

[1]  G. Peracchia,et al.  Radiotherapy with thrice-a-day fractionation in a short overall time: clinical experiences. , 1981, International journal of radiation oncology, biology, physics.

[2]  W. Bogaert,et al.  Radiotherapy with thrice-a-day-fractionation in a short overall time. , 1981 .

[3]  L. Peters,et al.  Relationship between lymph nodal status and primary tumor control probability in tumors of the supraglottic larynx. , 1985, International journal of radiation oncology, biology, physics.

[4]  L J Peters,et al.  Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. , 1988, Acta oncologica.

[5]  J BERKSON,et al.  Calculation of survival rates for cancer. , 1950, Proceedings of the staff meetings. Mayo Clinic.

[6]  J. M. Taylor,et al.  The hazard of accelerated tumor clonogen repopulation during radiotherapy. , 1988, Acta oncologica.

[7]  V. Svoboda Radiotherapy by several sessions a day. , 1975, The British journal of radiology.

[8]  J. Horiot,et al.  Early results of the EORTC randomized clinical trial on multiple fractions per day (MFD) and misonidazole in advanced head and neck cancer. , 1986, International journal of radiation oncology, biology, physics.

[9]  H. Suit,et al.  Twice‐a‐day radiation therapy for cancer of the head and neck , 1985, Cancer.

[10]  L. Peters,et al.  Concomitant boost radiotherapy for advanced squamous cell carcinoma of the head and neck. , 1985, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[11]  G. Fletcher,et al.  Accelerated fractionation vs hyperfractionation: rationales for several treatments per day. , 1983, International journal of radiation oncology, biology, physics.

[12]  J. Fowler,et al.  Radiotherapy employing three fractions on each of twelve consecutive days. , 1988, Acta oncologica.